@brassskate88
Active 1 month, 3 weeks ago
atment cycle may serve as a valuable prognostic marker in patients with advanced NSCLC. Routine clinical application with treatment reconsideration calls for further studies, preferably in prospective clinical trials.
Fruquintinib is an oral vascular endothelial growth factor receptor inhibitor. Previous gefitinib studies with […] View
-
Markussen Parker posted an update 1 month, 3 weeks ago
atment cycle may serve as a valuable prognostic marker in patients with advanced NSCLC. Routine clinical application with treatment reconsideration calls for further studies, preferably in prospective clinical trials.
Fruquintinib is an oral vascular endothelial growth factor receptor inhibitor. Previous gefitinib studies with anti-angiogenics…[Read more]
-
Markussen Parker became a registered member 1 month, 3 weeks ago
